| Category | Acne Care |
| Founded | 2012 |
| Headquarters | Shanghai |
| Listing | Private (Shanghai Ruizhi Medical Technology / Borunda Biochemistry (Shanghai)) |
| Latest revenue | No audited financials disclosed |
| Hero SKUs | Supramolecular Salicylic Acid Gel |
Brand History
Founded in 2012, Broda operates through Shanghai Ruizhi Medical Technology, with products developed by US-based Brodart International and Borunda Biochemistry (Shanghai) out of Zhangjiang. Its technical signature is controlled-release 'supramolecular' salicylic acid (IntelliGel): a hydrogel that encapsulates the acid for slow release, reducing the irritation of traditional BHA.
Broda's channel is unusual among Chinese clinical brands — it grew out of medical-aesthetics and dermatology 'acid peel' procedures: professional lines in clinics first, then spillover to e-commerce via doctor and clinic word of mouth. A 2% gel and a salicylic mask form the core, at RMB 100-300 between drug products and ordinary cosmetics. As 'acid peeling' claims came under cosmetic regulation, the brand's assets — professionalism, stated concentrations, clinical heritage — became scarcer, though cheaper, more digital-first domestic BHA products press it directly.
Hero Products
Three-Year Financials
Neither the brand nor its parent publishes audited annual financials; no estimates are provided.
Brand-level：Revenue is not public. Available information shows Broda sells mainly through medical-aesthetics clinics, dermatology channels and a professional online line, with the 2% salicylic gel as its core SKU.
Source：Broda official website; brand materials; trade press
Company Coverage
- 2025-11Acid claims tighten
Cosmetic claim rules highlight the compliance edge of clinical-line brands.
Source：Trade media - 2025-06Clinic channel stabilises
Recovering clinic traffic lifts professional-line repurchase.
Source：Trade media - 2024-12Domestic BHA competition
Cheaper domestic acid products enter the same price band.
Source：E-commerce analysis
Editor's note: Broda stands for China's 'institutional brand' model — a salicylic acid dermatologists are willing to recommend and patients ask about. The path is slow but harder to copy than e-commerce spend. Tighter regulation is a tailwind; the real risk is that once 'professional' becomes generic, it must prove its controlled-release technology is a felt difference, not a formula footnote.